Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Oral Anti-CD3 and Bioencapsulated FVIII Therapy Exhibit Distinct Mechanisms That Suppress Inhibitor Formation in Hemophilia a

Moanaro Biswas, Thais Bertolini, Kaman So, Jyoti Rana, Sandeep R.P. Kumar, Sha Cao, Hongyu Gao, Xiaoling Xuei, Henry Daniell, Roland W. Herzog

Blood (2022) 140 (Supplement 1): 11273–11274.

https://doi.org/10.1182/blood-2022-169734

Published: 2022

Journal Articles

Factor IX Delivery to the Skin Primes Inhibitor Formation and Sensitizes Hemophilia B Mice to Systemic Factor IX Administration

Radoslaw Kaczmarek, Thais Bertolini, Roland W Herzog, Alexandra Sherman

Blood (2021) 138 (Supplement 1): 3194.

https://doi.org/10.1182/blood-2021-154146

Published: 2021

Journal Articles

Helper T Cell Response to Factor VIII In Vivo Requires Several Anatomically Distinct Types of Antigen Presenting Cells

Radoslaw Kaczmarek, Annie R Pineros, Matthew Carl Arvin, Thais Bertolini, Rodney M. Camire, Roland W Herzog

Blood (2021) 138 (Supplement 1): 440.

https://doi.org/10.1182/blood-2021-146059

Published: 2021

Journal Articles

Alternative Approaches to Oral Tolerance Induction to Factor FVIII

Thais Bertolini, Moanaro Biswas, PhD, Radoslaw Kaczmarek, PhD, Henry Daniell, PhD, Roland W Herzog, PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142661

Published: 2020

Journal Articles

Revisiting the "Danger Theory": Toll-like Receptor 9 Stimulation Triggers Activation of Conventional CD8α + and Plasmacytoid Dendritic Cells En Route to Enhancing FVIII Inhibitor Formation

Radoslaw Kaczmarek, PhD, Thais Bertolini, Roland W Herzog, PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143259

Published: 2020

Journal Articles

AAV Vector Dose Determines TLR9 Dependence of CD8+ T Cell Response to Transgene Product

Ning Li, Thais Bertolini, Roland W Herzog, PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-141054

Published: 2020

NARROW

Oral Anti-CD3 and Bioencapsulated FVIII Therapy Exhibit Distinct Mechanisms That Suppress Inhibitor Formation in Hemophilia a

Factor IX Delivery to the Skin Primes Inhibitor Formation and Sensitizes Hemophilia B Mice to Systemic Factor IX Administration

Helper T Cell Response to Factor VIII In Vivo Requires Several Anatomically Distinct Types of Antigen Presenting Cells

Alternative Approaches to Oral Tolerance Induction to Factor FVIII

Revisiting the "Danger Theory": Toll-like Receptor 9 Stimulation Triggers Activation of Conventional CD8α + and Plasmacytoid Dendritic Cells En Route to Enhancing FVIII Inhibitor Formation

AAV Vector Dose Determines TLR9 Dependence of CD8+ T Cell Response to Transgene Product

Email alerts

ASH Publications

American Society of Hematology

Oral Anti-CD3 and Bioencapsulated FVIII Therapy Exhibit Distinct Mechanisms That Suppress Inhibitor Formation in Hemophilia a

Factor IX Delivery to the Skin Primes Inhibitor Formation and Sensitizes Hemophilia B Mice to Systemic Factor IX Administration

Helper T Cell Response to Factor VIII In Vivo Requires Several Anatomically Distinct Types of Antigen Presenting Cells

Alternative Approaches to Oral Tolerance Induction to Factor FVIII

Revisiting the "Danger Theory": Toll-like Receptor 9 Stimulation Triggers Activation of Conventional CD8α + and Plasmacytoid Dendritic Cells En Route to Enhancing FVIII Inhibitor Formation

AAV Vector Dose Determines TLR9 Dependence of CD8+ T Cell Response to Transgene Product

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only